TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether TRI102 is effective in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children ages 6-12.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tris Pharma, Inc.
• Treatments: Amphetamine

Criteria

Inclusion Criteria:

• Children aged 6 to 12 years with ADHD who require pharmacologic treatment for this condition

Exclusion Criteria:

• Other serious illnesses or conditions that would put the patient at particular risk for safety events or would interfere with treatment/assessment of ADHD